Eloxx Pharmaceuticals (ELOX) Insider & Congress Trades

Smart money at a glance

Filings to Nov 14, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about ELOX filings

Are insiders buying or selling Eloxx Pharmaceuticals, Inc. (ELOX) stock?

Neither. Eloxx Pharmaceuticals, Inc. (ELOX) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded ELOX recently?

None. No member of Congress disclosed a ELOX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ELOX smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

No recent filings found.

Questions about ELOX filings

Are insiders buying or selling Eloxx Pharmaceuticals, Inc. (ELOX) stock?

Neither. Eloxx Pharmaceuticals, Inc. (ELOX) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded ELOX recently?

None. No member of Congress disclosed a ELOX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ELOX smart-money data?

Checking federal contract awards

Unlock everything for $29/month

Unlock for $29/month

Earnings

Results versus expectations

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Sep 11, 2026

Period ending

Dec 31, 2025

Earnings per share

Unavailable

EPS comparison unavailable

Revenue (FY)

$0.00

Year ended Dec 31, 2025 · SEC filing

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 10, 2026	Not on file	No estimate	Not on file	Not on file
Jun 30, 2026Reported Aug 11, 2026	Not on file	No estimate	$0.00Yahoo Finance	No year-ago quarter
Sep 30, 2023Reported Nov 12, 2023	-$14.41est. -$21.67	+33.50%beat	Not on file	Not on file
Jun 30, 2023Reported Aug 14, 2023	-$21.56est. -$16.94	-27.27%miss	Not on file	Not on file
Mar 31, 2023Reported Apr 3, 2023	-$31.68est. -$28.05	-12.94%miss	Not on file	Not on file
Dec 31, 2022Reported Mar 31, 2023	-$2.92est. -$2.97	+1.68%beat	Not on file	Not on file
Sep 30, 2022Reported Nov 10, 2022	-$39.60est. -$48.40	+18.18%beat	Not on file	Not on file
Jun 30, 2022Reported Aug 15, 2022	-$52.80est. -$45.47	-16.12%miss	Not on file	Not on file

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $12.95
High: $13.00
Low: $12.77
Prev close: $13.01
52-wk high: $23.40
52-wk low: $8.20
Mkt cap: $52.5M
P/E: 3.7x
ROE: +0.0%
Beta: -169204.95
P/B: 1.1x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

Fairly priced and running thin margins.

Net margin: 0.0%
P/E: 3.70
Market cap: $53M

Valuation

P/B1.14

Quality

Operating margin0.0%
ROE0.0%
ROA0.0%

Growth

Beta-169204.95

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

15 / 100

RSI 14

51balanced

20D volatility

54%annualized

52-week range

$12.89

$8.20$23.40

20D support

$11.53recent floor

20D resistance

$14.24recent ceiling

Returns

5D +0.7%20D -5.9%60D -29.0%

Price vs moving averages

SMA20 -1.0%SMA50 -11.2%

Volume pace

1.08xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Nov 10, 2026

Not on file

No estimate

Not on file

Jun 30, 2026Aug 11, 2026

Not on file

No estimate

$0.00Yahoo Finance

No year-ago quarter

Sep 30, 2023Nov 12, 2023

-$14.41est. -$21.67

+33.50%

Not on file

Jun 30, 2023Aug 14, 2023

-$21.56est. -$16.94

-27.27%

Not on file

Mar 31, 2023Apr 3, 2023

-$31.68est. -$28.05

-12.94%

Not on file

Dec 31, 2022Mar 31, 2023

-$2.92est. -$2.97

+1.68%

Not on file

Sep 30, 2022Nov 10, 2022

-$39.60est. -$48.40

+18.18%

Not on file

Jun 30, 2022Aug 15, 2022

-$52.80est. -$45.47

-16.12%

Not on file

Eloxx Pharmaceuticals, Inc.

Smart money at a glance

What do analysts expect?

Questions about ELOX filings

Questions about ELOX filings

How top traders are positioned

Unlock everything for $29/month

Results versus expectations

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Eloxx Pharmaceuticals, Inc.

Smart money at a glance

What do analysts expect?

Questions about ELOX filings

Questions about ELOX filings

How top traders are positioned

Unlock everything for $29/month

Results versus expectations

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Eloxx Pharmaceuticals, Inc.

Overview

Questions about ELOX filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Eloxx Pharmaceuticals, Inc.

Overview

Questions about ELOX filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.